These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34683871)

  • 21. Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models.
    Wang D; Lu J; Li Q; Li Z
    Exp Ther Med; 2019 May; 17(5):4023-4031. PubMed ID: 31007740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
    Polepally AR; Mensing S; Khatri A; Beck D; Liu W; Awni WM; Menon RM; Dutta S
    Clin Pharmacokinet; 2016 Sep; 55(9):1091-101. PubMed ID: 27000758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
    Zhang L; Wicha WW; Bhavnani SM; Rubino CM
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients.
    Al-Huniti N; Chapel S; Xu H; Bui KH; Sostek M
    Br J Clin Pharmacol; 2016 Jan; 81(1):89-100. PubMed ID: 26317320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].
    Xuan JW; Zhang ZY; Wang YF; Mao ZG; Lu YJ; Wang RZ
    Zhonghua Yi Xue Za Zhi; 2017 Mar; 97(10):765-769. PubMed ID: 28316158
    [No Abstract]   [Full Text] [Related]  

  • 27. Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.
    Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
    Clin Pharmacokinet; 2017 Apr; 56(4):421-433. PubMed ID: 27743205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR
    Delemer B; Nguyen-Tan-Hon T; Coriat R; Smith D; Schillo F; Raingeard I; Sobhani I; Etienne PL; Decoudier B; Bisot-Locard S; Santos A; Raverot G; Cadiot G
    Adv Ther; 2020 Sep; 37(9):3901-3915. PubMed ID: 32683667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained-release delivery of octreotide from biodegradable polymeric microspheres.
    Rhee YS; Sohn M; Woo BH; Thanoo BC; DeLuca PP; Mansour HM
    AAPS PharmSciTech; 2011 Dec; 12(4):1293-301. PubMed ID: 21948321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):279-92. PubMed ID: 21347679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients.
    Tatami S; Sarashina A; Yamamura N; Igarashi T; Tanigawara Y
    Drug Metab Pharmacokinet; 2003; 18(3):203-11. PubMed ID: 15618736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
    Wémeau JL; Caron P; Beckers A; Rohmer V; Orgiazzi J; Borson-Chazot F; Nocaudie M; Perimenis P; Bisot-Locard S; Bourdeix I; Dejager S
    J Clin Endocrinol Metab; 2005 Feb; 90(2):841-8. PubMed ID: 15562016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants.
    Song L; He CY; Yin NG; Liu F; Jia YT; Liu Y
    Oncotarget; 2017 Dec; 8(62):105211-105221. PubMed ID: 29285245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
    Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I.
    Martinez JM; Brunet A; Hurbin F; DiCioccio AT; Rauch C; Fabre D
    Clin Pharmacokinet; 2019 Jan; 58(1):101-113. PubMed ID: 29725996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
    Arts J; Caenepeel P; Bisschops R; Dewulf D; Holvoet L; Piessevaux H; Bourgeois S; Sifrim D; Janssens J; Tack J
    Clin Gastroenterol Hepatol; 2009 Apr; 7(4):432-7. PubMed ID: 19264574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study.
    Wang D; Chen X; Li Z
    Oncol Lett; 2019 Sep; 18(3):2412-2419. PubMed ID: 31452734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetics of
    Jang JH; Jeong SH; Cho HY; Lee YB
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31614996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research.
    Tabata K; Hamakawa N; Sanoh S; Terashita S; Teramura T
    Eur J Drug Metab Pharmacokinet; 2009; 34(2):117-28. PubMed ID: 19645221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.